Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert Shepard

Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

Related publications

Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Lymphoma, Myeloma and Leukemia

English

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology

English

In Vitro Cellular Drug Resistance in Children With Relapsed/Refractory Acute Lymphoblastic Leukemia

English

Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma

English

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

American Journal of Hematology

Hematology

2018

English

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

Klinicheskaya Onkogematologiya/Clinical Oncohematology

Oncology

Hematology

2017

English

A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Robert Shepard

Phase I/Ii Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Related publications

Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

In Vitro Cellular Drug Resistance in Children With Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase I Trial of SAR103168, a Novel Multi-Kinase Inhibitor, in Patients With Refractory/Relapsed Acute Leukemia or High-Risk Myelodysplastic Syndrome

Potent Anti-Leukemia Activities of Humanized CD19-targeted CAR-T Cells in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Bortezomib Combination Therapy of Relapsed and Refractory Acute Lymphoblastic Leukemia in Children

A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States